Recent studies verified that abnormal activation of STAT3 signalling mediates cisplatin sensitivity in several cancers, such as breast cancer, OSCC, oesophageal squamous cell carcinoma and ovarian cancer and lung cancer40–44. This evidence concerns the gene STAT3 and ovarian cancer.